

## FRANKLIN TEMPLETON INVESTMENT FUNDS

### FRANKLIN BIOTECHNOLOGY DISCOVERY FUND



	Fund name	ISIN	Reporting Period	Statement Under Regulation 92(1)(e) *	Excess of Reported Income per Unit in Base CCY	Base CCY	Fund Distribution Date	Distribution Date - N/A		
								Rate per share in Base	Base CCY	Dist Type
	Franklin Biotechnology Discovery Fund I (Acc) USD	LU0195948822	01/07/2011 to 30/06/2012	Y	0.0000	USD	31 December 2012	N/A	USD	Acc
	Franklin Biotechnology Discovery Fund A (Acc) USD	LU0109394709	01/07/2011 to 30/06/2012	Y	0.0000	USD	31 December 2012	N/A	USD	Acc
	Franklin Biotechnology Discovery Fund Z (Acc) GBP	LU0774687577	04/05/2012 to 30/06/2012	Y	0.0000	USD	31 December 2012	N/A	USD	Acc

\* The Fund remains a reporting fund for the purposes of the Regulations as at the Fund Publication date

Copyright © 2012 Franklin Templeton Investments. All rights reserved.

This document is intended to be of general interest only and does not constitute legal or tax advice nor is it an offer for shares or invitation to apply for shares of the Franklin Templeton Investment Funds, a Luxembourg-registered SICAV. Nothing in this document should be construed as investment advice.

Subscriptions to shares of the fund can only be made on the basis of the current Fund's prospectus and the relevant Key Investor Information Document, accompanied by the latest available audited annual report and the latest semi-annual report if published thereafter. An investment in the Fund entails risks which are described in the Fund's prospectus and the relevant Key Investor Information Document.

The value of shares in the fund and income received from it can go down as well as up, and investors may not get back the full amount invested.

Currency fluctuations may affect the value of overseas investments. When investing in a fund denominated in a foreign currency, your performance may also be affected by currency fluctuations. In emerging markets, the risks can be greater than in developed markets. Funds with investments in derivative instruments entail specific risks that may increase the risk profile of the fund and are more fully described in the fund's prospectus. Funds that invest in a specific sector or geographical area may have more volatile returns than a more diversified fund. No shares of the fund may be directly or indirectly offered or sold to nationals or residents of the United States of America. Shares of the fund are not available for distribution in all jurisdictions and prospective investors should confirm availability with their local Franklin Templeton Investments representative before making any plans to invest. All or most of the protections provided by the UK Regulatory System will not apply to Franklin Templeton Investment Funds (SICAV) Investors.

For a free copy of the latest prospectus and the relevant Key Investor Information Document, the annual report and semi-annual report, if published thereafter or for more information about any Franklin Templeton Investments' fund, UK investors should contact: Franklin Templeton Investments, Telephone: 0800 305 306, Email: [enquiries@franklintempleton.co.uk](mailto:enquiries@franklintempleton.co.uk) or write to us at the address below. Issued by Franklin Templeton Investment Management Limited (FTIML) Registered office: The Adelphi, 1-11 John Adam Street, London WC2N 6HT. FTIML is authorised and regulated by the Financial Services Authority.